Evidence map›Paper›PMID 40768107›Full record

ArticleClinical rheumatology2025

Suboptimal methotrexate utilization in Chinese patients with inflammatory arthritis: data from a Chinese center.

Qian Wang, Yang Zhang, Hua Zhang, Zhiyong Chen, Miao Chen, Sheng-Ming Dai

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qian Wang *Department of Rheumatology and Immunology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yang Zhang *Department of Pharmacy, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.
Hua ZhangDepartment of Rheumatology and Immunology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhiyong ChenDepartment of Rheumatology and Immunology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Miao ChenDepartment of Rheumatology and Immunology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. chenmiao2011@126.com.
Sheng-Ming DaiDepartment of Rheumatology and Immunology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. shengmingdai@163.com.ORCID http://orcid.org/0000-0001-8876-4205

Funding

Beijing Medical Award Foundation YXJL-2023-0270-0303Shanghai Sixth People's Hospital Fund ynts202307
6 · The paper itself

Abstract

objectiveMethotrexate (MTX) is a cornerstone treatment for inflammatory arthritis and its suboptimal usage can lead to low therapeutic response rates. We aim to describe the situation of daily usage of MTX among Chinese patients.

methodsWe conducted a retrospective cross-sectional survey in consecutive outpatients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA). A structured questionnaire was developed to collect data on current or previous MTX usage, including dosage, combination therapies, and incidence of side effects. Adherence rates were calculated.

resultsA total of 340 patients with RA and 97 patients with PsA were included. Among them, 276 (81.2%) patients with RA and 78 (80.4%) patients with PsA were currently taking MTX. The average dosage of current MTX use was 9.68 ± 1.65 mg/week in patients with RA and 9.68 ± 1.15 mg/week in patients with PsA, with a range of 2.5-15 mg/week. The adherence rates were 74.6% in RA and 74.4% in PsA. Only 9.8% of patients with RA and 5.1% of patients with PsA received MTX monotherapy currently. MTX withdrawal occurred in 64 (18.8%) patients with RA and 19 (19.6%) in patients with PsA. The major reasons for MTX withdrawal were nausea (33.7%) and abnormal liver function (32.5%). Among the patients who discontinued MTX, 20 (24.1%) patients refused to take MTX due to worrying about the possible side effects.

conclusionA high rate of inadequate dosage of MTX was used among Chinese patients with inflammatory arthritis, suggesting that MTX might not fully exert its therapeutic efficacy. Key Points • MTX dosage was inadequate among Chinese patients. • MTX adherence rates were suboptimal.

Indexed as

Antirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidMethotrexateAdultAgedChinaCross-Sectional StudiesDrug Therapy, CombinationEast Asian PeopleFemaleHumansMaleMiddle AgedRetrospective StudiesSurveys and QuestionnairesAntirheumatic AgentsMethotrexateDosageMethotrexatePsoriasis arthritisRheumatoid arthritis

Identifiers

PMID40768107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.